NPIL Research and Deveopment (NRDL), which was recently demerged from Nicholas Piramal India, has commenced Phase-1 studies of a new experimental drug molecule, P1 201-07, in The Netherlands.
The company had submitted the clinical trial application (CTA) for P1201-07 to the central committee on research involving human subjects (CCMO), the regulatory authority of The Netherlands and the independent ethics committee of the foundation Evaluation Of Ethics in Biomedical Research (BEBO), Assen, The Netherlands. Both the bodies have approved the company's application to initiate Phase-I study of P1201-07.
"This is our fourth new drug to enter the clinic and the first from the research collaboration with pharma major Eli Lilly. The drug development timeline is on schedule. We in-licensed this molecule from Lilly in January 2007, and it has gone to the clinic in just a year," said Dr. Swati Piramal, director, strategic alliances & communications, NPIL.
Buy Microsoft Products with us and Save upto 60%
Tuesday, February 26, 2008
Nicholas R&D starts trials in The Netherlands
Friday, February 15, 2008
Nicholas R&D firm signs deal with Eli Lilly
NPIL Research & Development (NRDL) has signed a second new drug development agreement with Eli Lilly and Company to develop, and in certain regions commercialise, a select group of Eli Lilly's pre-clinical drug candidates that span multiple therapeutic areas.
According to a release issued by Nicholas Piramal (NPIL) to the BSE today, the new NRDL-Lilly alliance generally follows the framework established by the earlier agreement between NPIL and Lilly signed on January 12, 2007, and continues the rationale of seeking to increase productivity in drug development by synergising the unique strengths of both companies and equitably sharing risk and reward.
"The second agreement includes an innovative structure that may improve the probability of success of the programme. In this new agreement, both NRDL and Lilly will independently carry out early clinical development of two different candidate compounds directed against the same target. Following the evaluation of the data from the proof-of-concept studies, one or more of the drug candidates may be selected for further development. NRDL's compensation, based on a pre-agreed formula, could total up to $110 million in call-back payments and milestones plus royalties on sales," the release added.
Dr. Swati Piramal, director (strategic alliances & communications), NPIL, said: "We are strengthening our R&D collaboration with Eli Lilly as our first agreement is on track and has seen benefits accruing to both partners in terms of cost, quality and time. These partnerships are a win-win for both companies, and will help us to reduce the burden of human disease."
Friday, January 18, 2008
Nicholas consolidated net up 31% at Rs 73cr
Nicholas Piramal consolidated Q3 net profit for the quarter ended December 2007 surged 31% to Rs 72.76 crore when compared with Rs 55.55 crore in the corresponding quarter a year ago.
According to a release issued by the company to the BSE today, total income increased 13.3% to Rs 736.35 crore in Q3FY08 from Rs 649.70 crore in Q3FY07.
On a stand-alone basis, the company's bottomline soared 70.5.% to Rs 73.82 crore in Q3FY08 as against Rs 43.30 crore in Q3FY07. Total income grew 20.6% to Rs 492.18 crore from Rs 408.04 crore.
Wednesday, December 19, 2007
Welspun acquires Portuguese bath rug firm
Welspun India, a home textiles firm and a part of Welspun group, has acquired 76% stake in Portuguese bath rug firm, Sorema-Tapates e Cortinas de Banho at an enterprise value of Rs 60 crore.
It is Welspun's second overseas acquisition in less than a year's time in the towel business. In July last year, the company had acquired 85% stake in UK-based towel brand Christy.
The company's share prices today closed at Rs 99.05, down 2.12% on the BSE.
Nicholas, Japan's Arkray in diagnostics JV
Nicholas Piramal India (NPIL) has entered into a joint venture with Arkray of Japan to market diagnostic products, mainly self-monitoring blood glucose systems, in the Indian market.
NPIL will transfer its existing blood glucose monitoring business into the 49:51 joint venture for a consideration of Rs 4 crore. The JV will market these products and will also launch other blood glucose-monitoring equipment of the Japanese partner, said an NPIL statement.
"India has about 41 million people who suffer from diabetes. By collaborating with Arkray, NPIL plans to bring all the latest technology in blood glucose monitoring products launched by Arkray to India," said Swati Piramal, director - strategic alliances and communications, NPIL.
The blood glucose system market in India is estimated to be more than Rs 100 crore in size and is estimated to be growing at around 20% per annum.
Kyoto-based Arkray is a market leader in the self- monitoring blood glucose market in Japan with a dominant market share and its products are also distributed in over 80 countries around the world, said the statement.
